1. Alexander BM, Mehta MP. Role of isocitrate dehydrogenase in glioma. Expert Rev Neurother 2011; 11: 1399-1409.
2.
Berghoff1 AS, Stefanits H, Woehrer A, Heinzl H, Preusser M, Hainfellner JA. Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 2013; 32: 148-158.
3.
Capper D, Zentgraf H, Balss J, Hartmann C, Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118: 599-601.
4.
Central Nervous System Tumors, WHO Classification of Tumours 5th edition. Editorial Board: Brat DJ, Ellison DW, 2021; 25, 34, 287.
5.
Çetin NB. Histopathological distribution of central nervous system tumors and incidence: 10-year retrospective analysis of a single center. Dicle Med J 2020; 47: 178-193.
6.
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, LundJohansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016; 17: 383-391.
7.
Grondahl TB, Moen BH, Arnli MB, Torseth K, Torp SH. Immunohistochemical characterization of brain-invasive meningiomas. Int J Clin Exp Pathol 2014; 7: 7206-7219.
8.
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718.
9.
Kuncova K, Janda A, Kasal P, Zamecnik J. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis. Pathol Oncol Res 2009; 15: 605-614.
10.
Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 2006; 106: 388-395.
11.
Litofsky NS, Mix TC, Baker SP, Recht LD, Smith TW. Ki-67 (clone MIB-1) proliferation index in recurrent glial neoplasms: no prognostic significance. Surg Neurol 1998; 50: 579-585.
12.
Meningiomas: Their classification, regional behaviour, life history, and surgical end results. Editorial Board: Cushing H, Eisenhardt L. Published by Charles C. Thomas, Springfield, IL, 1938; 185.
13.
Ocak GAG, Gürer İE. Pathology and classification of brain tumors. Turkiye Klinikleri J Radiol Special Topics 2017; 10: 110-117.
14.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4: 41-462.
15.
Parsons DW, Jones S, Zhang X, Lin JC, Learry RJ, Angenent P, Mankoo P, Carter H, Siu I, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
16.
Pollack IF. Brain tumors in children. N Engl J Med 1994; 331: 1500-1507.
17.
Preusser M, Capper D, Hartmann C. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 2011; 30: 217-230.
18.
Preusser M, Heinzl H, Gelpi E, Höftberger R, Fischer I, Pipp I, Milenkovic I, Wöhrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008; 53: 39-47.
19.
Raabe E, Kieran MW, Cohen KJ. New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res 2013; 19: 4553-4558.
20.
Rzehak A, Sobstyl M, Bojarski P. Metastases to cranial base meningiomas. Clinical presentations and surgical outcomes. Literature overview. Folia Neuropathol 2022; 60: 375-383.
21.
Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol 2009; 24: 1397-1408.
22.
Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009; 360: 813-815.
23.
Weems TD, Garcia JH. Intracranial meningioma containing metastatic foci. South Med J 1977; 704: 503-505.
24.
Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 2004; 28: 914-920.
